• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » A New Medication for Narcolepsy [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts and Spotify.

A New Medication for Narcolepsy [60 Sec Psych]

October 28, 2020

Xyrem is a branded form of sodium oxybate, the sodium salt of gamma-hydroxybutyrate, or GHB , to precursor to GABA, glutamate, and glycine which is FDA approved for narcolepsy and cataplexy. The news on Xyrem is that the FDA just approved a new version of it – called Xywav – made by Jazz pharmaceuticals. [FDA Prescribing Information]


Date Published: 10/27/2020


Duration: 2 minutes, 4 seconds


Transcript:

Xyrem is a branded form of sodium oxybate, the sodium salt of gamma-hydroxybutyrate, or GHB , to precursor to GABA, glutamate, and glycine which is FDA approved for narcolepsy and cataplexy. You need to know about it because it’s a heavy sedative and respiratory depressant, and it’s a Schedule III drug of abuse that has also been used as a date rape drug and athletic performance enhancer. You need special certification to prescribe xyrem, and it’s primarily used by neurologists and sleep medicine doctors. Patients actually have to take this sedative in two doses and they have to wake up to take the second dose – first at bedtime and another dose 4 hours later.

You’ll also need to know about it because it’s been studied for alcoholism and fibromyalgia, though the latest fibrom yalgia study was negative.

The news on Xyrem is that the FDA just approved a new version of it – called Xywav – made by Jazz pharmaceuticals. Xywav adds calcium, magnesium, potassium to the mix as binding salts. In other words, while Xyrem is bound only to sodium, Xwav is bound to calcium, magnesium, potassium, and sodium. Both are liquid formulations and both have the same dosing instructions, risks and benefits.

Got feedback? Take the podcast survey.

Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.